OpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by T...
The AMW Read
OpenEvidence's $12B valuation and massive physician penetration validates the high-scale potential of vertical AI, while the $250M round and $12B valuation trigger the cross.Β§D threshold.
NoveltySignificance
Healthcare & Bio Β· Player MapCapital Cycles
OpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by Thrive Capital. Used by 50 percent of U.S. physicians and processing 18 million monthly consultations, the startup proves vertical AI can scale as fast as general models. This signals a systemic shift toward domain-specific intelligence where precision is non-negotiable. Its ad-based revenue model suggests a new path for AI monetization beyond traditional SaaS. π
